Peripheral sub- XXXX is associated with antidepressant consumption in @entity161 . Results from the multi-center FACE-SZ data set.

@entity1 @entity2298 @entity286 @entity308 @entity32 @entity101 @entity835 @entity1144 @entity161 @entity74 @entity716 @entity209 @entity413 @entity1851
OBJECTIVES: The relation between @entity1851 ( @entity1851 ), @entity308 and antidepressant consumption has been well explored in major @entity308 but not in @entity161 , which has a high rate of @entity308 comorbidity. The objectives of this study were: (i) to determine the prevalence of abnormal @entity1851 levels, @entity308 and antidepressant consumption in a multicenter community-dwelling sample of subjects with @entity161 (ii) to determine the association between abnormal @entity1851 levels, @entity308 and antidepressant consumption in @entity161 . METHOD: 219 stable @entity1 with @entity161 (mean age=31.6 years, 75.3% male gender) were systematically included in the multicentre network of FondaMental Expert Center for @entity161 (FACE-SZ) and assessed with a dedicated electronic medical record including the Structured Clinical Interview for DSM-IV @entity74 and Calgary @entity308 Scale for @entity308 . High sensitivity @entity1851 (hs- @entity1851 ) was measured with an assay using nephelometry (Dade Behring). Abnormal @entity1851 level was defined by levels >3mg/L. Current medication was recorded. RESULTS: Overall, 63 subjects (28.8%) were found to have abnormal @entity1851 levels, 43 (20.1%) received a diagnosis of comorbid current @entity308 , and 51 (31.9%) had ongoing antidepressant treatment. In univariate analysis, abnormal @entity1851 levels were found to be significantly associated with body mass index (BMI) (p<0.0001), @entity2298 (p=0.0015), high waist circumference (p<0.0001), @entity209 (p=0.0011), @entity1144 (p<0.0001) and with antidepressant consumption (p=0.01), while @entity308 , @entity716 symptomatology, age of onset, illness duration, sociodemographic characteristics, current @entity286 or @entity835 status, @entity101 or high fasting @entity413 were not (all p>0.05). In a multivariate model, abnormal @entity1851 was associated with antidepressant consumption independently of other confounding variables (adjusted Odds Ratio=2.8, 95% confidence interval 1.22-6.62). @entity209 was also independently associated with abnormal @entity1851 (adjusted Odds Ratio=2.6, 95% confidence interval 1.01-6.71). CONCLUSION: Abnormal @entity1851 levels in @entity161 were found to be associated with antidepressant consumption, but not with @entity308 . The potential mechanisms were discussed. Antidepressant consumption should be systematically recorded in future studies exploring @entity32 in @entity161 . Future clinical trials of interventions directed at lowering the level of  @entity1851  and other inflammatory markers are discussed.
